Available online at: http://www.iajps.com   Review Article

RECENT ADVANCES IN TARGETED DRUG DELIVERY FOR CANCER THERAPY: PHARMACOLOGICAL AND CLINICAL PERSPECTIVES

Rachana Santaji Kashid,[1]Simran Santosh Kamble[2],Vaibhavi Kasabekar[3],Aarti Baliram Bansode[4],Dr. Rahul Ishwara Jadhav[5]

DMKG College of Pharmacy, Mangalwedha

Abstract:
Cancer remains one of the leading causes of morbidity and mortality worldwide. Conventional chemotherapy often causes severe side effects due to lack of selectivity and damage to healthy tissues. Targeted drug delivery systems have emerged as promising strategies to improve therapeutic efficacy while minimizing systemic toxicity. These systems utilize various nanotechnology-based carriers such as liposomes, nanoparticles, dendrimers, and polymeric micelles to deliver drugs directly to tumor tissues. Targeted drug delivery can be achieved through passive targeting, active targeting, and stimuli-responsive mechanisms. Recent advances in pharmacological research have led to the development of several innovative targeted therapies including antibody-drug conjugates, ligand-based targeting, and nanocarrier-mediated drug delivery systems. These approaches enhance drug accumulation at tumor sites and improve treatment outcomes. This review discusses the principles of targeted drug delivery, recent pharmacological advances, clinical applications, and future perspectives in cancer therapy.
Keywords: Targeted drug delivery, cancer therapy, nanoparticles, nanomedicine, pharmacological advances, chemotherapy.

Corresponding author:
Aarti baliram bansode
aaratibandode1211999@gmail.com
DMKG college of pharmacy,Mangalwedha

QR CODE

Please cite this article in press Aarti baliram bansode et al., Recent Advances In Targeted Drug Delivery For Cancer Therapy: Pharmacological And Clinical Perspectives., Indo Am. J. P. Sci, 2026; 13(03).

1. INTRODUCTION:

Cancer is a complex disease characterized by uncontrolled cell growth and the ability to invade surrounding tissues and metastasize to distant organs. Despite significant advances in cancer research, it continues to be a major global health challenge. Traditional cancer treatments include surgery, radiation therapy, and chemotherapy. Among these, chemotherapy is widely used but often results in severe adverse effects because anticancer drugs are not selective for tumor cells. Conventional chemotherapy agents circulate throughout the body and damage both cancerous and normal cells. This lack of specificity leads to toxic side effects such as bone marrow suppression, gastrointestinal disturbances, and hair loss. Therefore, there is a growing need for drug delivery systems that can selectively target tumor tissues while minimizing harm to healthy cells.

Targeted drug delivery systems have emerged as an innovative approach to overcome these limitations. These systems use specialized carriers that transport therapeutic agents directly to tumor cells, thereby enhancing drug efficacy and reducing systemic toxicity.

Table 1. Types of Targeted Drug Delivery Systems Used in Cancer Therapy

Drug Delivery System	Description	Example
Liposomes	Spherical vesicles composed of lipid bilayers used to encapsulate drugs	Liposomal doxorubicin
Polymeric nanoparticles	Biodegradable polymer-based carriers that deliver drugs to tumor tissues	Paclitaxel nanoparticles
Dendrimers	Highly branched macromolecules with multiple functional groups for drug attachment	PAMAM dendrimers
Polymeric micelles	Nanocarriers formed by amphiphilic polymers for hydrophobic drugs	Docetaxel micelles
Solid lipid nanoparticles	Lipid-based carriers that enhance drug stability and bioavailability	Curcumin SLNs

Caption:
Types of nanocarrier-based targeted drug delivery systems commonly used in cancer therapy.

2. Principles of Targeted Drug Delivery

Targeted drug delivery refers to the process of delivering drugs specifically to diseased tissues while minimizing exposure to normal tissues. This approach improves therapeutic outcomes and reduces adverse effects.

Targeted delivery can be classified into three main strategies:

Passive Targeting

Passive targeting relies on the **enhanced permeability and retention (EPR) effect** observed in tumor tissues. Tumor blood vessels are more permeable than normal vessels, allowing nanoparticles and macromolecules to accumulate preferentially at tumor sites.

Active Targeting

Active targeting involves attaching specific ligands such as antibodies, peptides, or small molecules to drug carriers. These ligands bind to receptors that are overexpressed on cancer cells, facilitating selective drug uptake.

Stimuli-Responsive Targeting

Stimuli-responsive drug delivery systems release drugs in response to internal or external stimuli such as pH, temperature, enzymes, or magnetic fields.

Table 2. Mechanisms of Targeted Drug Delivery in Cancer Treatment

Targeting Strategy	Mechanism	Advantage
Passive Targeting	Utilizes enhanced permeability and retention (EPR) effect in tumors	Increased drug accumulation in tumor tissue
Active Targeting	Uses ligands such as antibodies or peptides to bind tumor receptors	Higher selectivity toward cancer cells
Stimuli-responsive targeting	Drug release triggered by pH, temperature, or enzymes	Controlled drug release
Magnetic targeting	Magnetic nanoparticles guided to tumor site using external magnetic field	Precise localization

Caption:
Different mechanisms used in targeted drug delivery to enhance selectivity toward tumor tissues.

3. Nanotechnology in Targeted Drug Delivery

Nanotechnology has revolutionized cancer treatment by enabling the development of advanced drug delivery systems.

3.1 Liposomes

Liposomes are spherical vesicles composed of lipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs. Liposomal formulations improve drug stability and reduce toxicity.

Example:

- Liposomal doxorubicin

3.2 Polymeric Nanoparticles

Polymeric nanoparticles are biodegradable carriers that can deliver drugs in a controlled manner. They protect drugs from degradation and improve bioavailability.

3.3 Dendrimers

Dendrimers are highly branched macromolecules that provide multiple functional groups for drug attachment and targeting.

3.4 Polymeric Micelles

Polymeric micelles are nanoscale structures capable of solubilizing hydrophobic anticancer drugs and improving their delivery to tumor tissues.

Mechanism of Targeted Drug Delivery in Cancer

Caption: Mechanism of targeted drug delivery showing nanoparticle-mediated drug transport, receptor-ligand interaction, and selective accumulation in tumor cells.

Table 3. Common Nanocarriers Used for Cancer Drug Delivery

Nanocarrier	Size Range	Advantages	Limitations
Liposomes	50–200 nm	Biocompatible, improves drug stability	Limited drug loading
Polymeric nanoparticles	10–1000 nm	Controlled drug release	Complex manufacturing
Dendrimers	1–15 nm	High drug loading capacity	Possible toxicity
Carbon nanotubes	1–100 nm	High surface area for drug attachment	Safety concerns
Gold nanoparticles	10–100 nm	Useful for imaging and therapy	High cost

Caption:
Comparison of nanocarriers used for targeted drug delivery in cancer therapy.

4. Antibody-Drug Conjugates (ADCs)

An advanced class of targeted anticancer therapies designed to improve the selectivity and effectiveness of chemotherapy. These agents consist of three main components: a monoclonal antibody, a cytotoxic (anticancer) drug, and a chemical linker that connects the drug to the antibody. The monoclonal antibody is specifically engineered to recognize and bind to antigens that are highly expressed on the surface of cancer cells. Once the antibody binds to the tumor antigen, the ADC is internalized into the cancer cell through receptor-mediated endocytosis. Inside the cell, the linker is cleaved, releasing the cytotoxic drug, which then destroys the cancer cell by interfering with essential cellular processes such as microtubule function or DNA replication. This targeted delivery system allows the anticancer drug to be concentrated within tumor cells while minimizing damage to normal tissues, thereby reducing systemic toxicity compared to conventional chemotherapy. Examples of clinically approved ADCs include **Trastuzumab emtansine**, which is used in the treatment of HER2-positive breast cancer, and **Brentuximab vedotin**, commonly used for Hodgkin lymphoma and certain types of non-Hodgkin lymphoma. These therapies have shown significant clinical benefits by improving treatment efficacy and patient outcomes in specific cancer types

.**Table 4. FDA-Approved Targeted Nanomedicines for Cancer Treatment**

Drug	Delivery System	Indication
Doxil	Liposomal doxorubicin	Ovarian cancer
Abraxane	Albumin-bound paclitaxel nanoparticles	Breast cancer
Onivyde	Liposomal irinotecan	Pancreatic cancer
Myocet	Liposomal doxorubicin	Breast cancer
DaunoXome	Liposomal daunorubicin	Kaposi's sarcoma

Caption:
Examples of FDA-approved nanomedicine formulations used in cancer therapy.

5. Clinical Applications of Targeted Drug Delivery
Table 5. Advantages and Limitations of Targeted Drug Delivery Systems

Advantages	Limitations
Improved drug accumulation in tumor tissues	High development cost
Reduced systemic toxicity	Complex manufacturing process
Enhanced therapeutic efficacy	Stability issues
Controlled and sustained drug release	Limited clinical translation

Caption:
Major advantages and challenges associated with targeted drug delivery systems.

Targeted drug delivery systems have become an important strategy in the treatment of various types of cancer because they allow anticancer drugs to be delivered directly to tumor cells while minimizing damage to healthy tissues. These systems use specialized carriers such as nanoparticles, liposomes, and antibody-drug conjugates to selectively transport therapeutic agents to cancer cells that express specific receptors or antigens. As a result, targeted therapies are currently applied in the management of several cancers including breast cancer, lung cancer, prostate cancer, leukemia, and lymphoma. By concentrating the drug at the tumor site, these delivery systems enhance treatment effectiveness and reduce the adverse effects commonly associated with conventional chemotherapy. In recent years, several nanomedicine-based formulations have been approved for clinical use, and many of them have demonstrated improved therapeutic outcomes such as better drug bioavailability, enhanced tumor targeting, and improved patient survival rates. Consequently, targeted drug delivery has emerged as a promising approach for improving the safety and efficacy of modern cancer therapy.

Table 6. Emerging Strategies in Targeted Cancer Drug Delivery

Strategy	Description	Potential Benefits
Antibody-drug conjugates	Antibody linked with cytotoxic drug	Highly selective targeting
Gene therapy	Delivery of therapeutic genes to tumor cells	Long-term therapeutic effect
CRISPR-based therapy	Gene editing approach to eliminate cancer-causing mutations	Precision therapy
Smart nanoparticles	Stimuli-responsive nanocarriers	Controlled drug release

Caption:
Emerging technologies that may improve targeted drug delivery in cancer therapy.

6. Advantages of Targeted Drug Delivery
Targeted drug delivery systems provide several significant advantages over conventional chemotherapy in cancer treatment. One of the major benefits is the increased concentration of the therapeutic drug at the tumor site, which enhances the effectiveness of the treatment. By specifically directing the drug toward cancer cells, these systems help reduce systemic toxicity and minimize damage to healthy tissues, thereby lowering the severity of side effects commonly associated with traditional chemotherapy. Additionally, targeted drug delivery improves overall therapeutic efficacy because the drug is delivered in a more precise and efficient manner. Many targeted delivery systems are also designed to provide controlled or sustained drug release, allowing the medication to act over a longer period and maintain optimal drug levels in the body. Furthermore, these systems can improve patient compliance, as targeted therapies often require lower doses and may reduce the frequency of drug administration, making the treatment more convenient and tolerable for patients.

7. Challenges in Targeted Drug Delivery
Despite the numerous advantages of targeted drug delivery systems in cancer therapy, several challenges still limit their widespread clinical application. One major limitation is the **restricted drug loading capacity** of certain nanocarriers, which can reduce the amount of therapeutic agent delivered to the tumor site. In addition, **stability issues** may arise during storage or circulation in the bloodstream, potentially affecting the effectiveness and shelf life of the drug formulation. Another important challenge is the **high production cost** associated with the development of advanced nanocarriers and targeted delivery technologies, which can make these treatments expensive and less accessible. Furthermore, there are **difficulties in large-scale manufacturing**, as maintaining

consistent quality, particle size, and drug loading during mass production can be technically complex. Therefore, continued research and technological improvements are essential to overcome these limitations and to enhance the safety, efficiency, and commercial feasibility of targeted drug delivery systems in cancer therapy.

8. FUTURE PERSPECTIVES:
Future research in targeted drug delivery is focused on developing more efficient and personalized therapies. Advances in nanotechnology, biotechnology, and molecular biology are expected to produce highly selective drug delivery systems capable of targeting specific cancer cells.

Emerging technologies such as **gene therapy, CRISPR-based editing, and smart nanoparticles** may further revolutionize cancer treatment in the coming years.

9. CONCLUSION:
Targeted drug delivery systems represent a promising approach for improving cancer treatment. By selectively delivering drugs to tumor cells, these systems reduce systemic toxicity and enhance therapeutic effectiveness. Nanotechnology-based carriers, antibody-drug conjugates, and ligand-mediated targeting strategies have significantly advanced cancer pharmacotherapy.

Although several challenges remain, ongoing research and technological innovations are expected to further improve targeted drug delivery systems. These advancements may lead to more effective and safer cancer treatments in the future.

REFERENCES:
1. Torchilin VP. Targeted drug delivery systems. Nat Rev Drug Discov.
2. Peer D. Nanocarriers as emerging platform for cancer therapy. Nat Nanotechnol.
3. Allen TM. Liposomal drug delivery systems. Nat Rev Cancer.
4. Duncan R. Polymer therapeutics in cancer. Nat Rev Cancer.
5. Maeda H. The enhanced permeability and retention effect. J Control Release.
6. Jain RK. Delivery of molecular medicine to tumors. Science.
7. Ferrari M. Cancer nanotechnology. Nat Rev Cancer.
8. Bae YH. Nanoparticle drug delivery. J Control Release.
9. Sengupta S. Targeted drug delivery in cancer. Nature.
10. Wang AZ. Nanoparticle delivery systems. Nat Rev Drug Discov.
11. Chari RV. Antibody-drug conjugates for cancer therapy. Angew Chem.
12. Park K. Nanotechnology in cancer therapy. J Control Release.
13. Shi J. Nanotechnology in drug delivery. ACS Nano.
14. Zhang L. Nanoparticles in cancer therapy. Nat Biotechnol.
15. Sahoo SK. Targeted drug delivery in cancer. Drug Discov Today.
16. Davis ME. Nanoparticle therapeutics. Nat Rev Drug Discov.
17. Brannon-Peppas L. Nanotechnology in cancer therapy. Adv Drug Deliv Rev.
18. Matsumura Y. Enhanced permeability of tumors. Cancer Res.
19. Farokhzad OC. Targeted nanoparticle therapy. Proc Natl Acad Sci.
20. Peer D. Nanomedicine for cancer therapy. Nat Nanotechnol.